| Bioactivity | UCL 2077 is a selective slow-afterhyperpolarization (sAHP) channel blocker (IC50 = 500 nM in hippocampal neurons in culture), having minimal effects on Ca2+ channels, action potentials, input resistance and the medium after hyperpolarization[1]. UCL 2077 is also a subtype-selective blocker of the epilepsy associated KCNQ channels[2]. |
| Target | sAHP. |
| Name | UCL 2077 |
| CAS | 918311-87-2 |
| Formula | C25H22N2 |
| Molar Mass | 350.46 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Shah MM, et al. Enhancement of hippocampal pyramidal cell excitability by the novel selective slow-afterhyperpolarization channel blocker 3-(triphenylmethylaminomethyl)pyridine (UCL2077). Mol Pharmacol. 2006 Nov;70(5):1494-502. [2]. Soh H, et al. The specific slow afterhyperpolarization inhibitor UCL2077 is a subtype-selective blocker of the epilepsy associated KCNQ channels. Mol Pharmacol. 2010 Dec;78(6):1088-95. |